Paradoxical echinocandin activity: a limited in vitro phenomenon?

References

• Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480–1489
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12: 1313–1333
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519–1527
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472–2482
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292–299
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337–349
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47–51
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331–1336
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187–1192
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W, et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968–974
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464–1471
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006; 50: 3695–3700
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539–550
   PubMed Web of Science ®Google Scholar
• Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058–5068
   PubMed Web of Science ®Google Scholar
• Hall GS, Myles C, Pratt KJ, Washington JA. Cilofungin (LY121019), an antifungal agent with specific activity against Candida, albicans and Candida tropicalis. Antimicrob Agents Chemother 1988; 32: 1331–1335
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257–2259
   PubMed Web of Science ®Google Scholar
• Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634–3636
   PubMed Web of Science ®Google Scholar
• Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081–3088
   PubMed Web of Science ®Google Scholar
• Seidler M, Salvenmoser S, Muller FM. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int J Antimicrob Agents 2006; 28: 568–573
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146–5148
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407–3411
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008; 52: 321–328
   PubMed Web of Science ®Google Scholar
• Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005; 43(Suppl. 1)S299–305
   Web of Science ®Google Scholar
• Wiederhold, NP, Kontoyiannis, DP, Prince, RA, Lewis, RE. Eagle-like effect of caspofungin against Candida and Aspergillus spp.: association with homeostatic mechanisms of cell wall integrity. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 30 October–2 November, 2004; Washington, DC; 2004M-1682.
   Google Scholar
• Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827–4833
   PubMed Web of Science ®Google Scholar
• Pringle JR, Preston RA, Adams AE, et al. Fluorescence microscopy methods for yeast. Methods Cell Biol 1989; 31: 357–435
   PubMed Web of Science ®Google Scholar
• Coen M, Bodkin J, Power D, et al. Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy. Antimicrob Agents Chemother 2006; 50: 4018–4026
   PubMed Web of Science ®Google Scholar
• Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005; 51: 173–178
   PubMed Web of Science ®Google Scholar
• Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 3160–3161
   PubMed Web of Science ®Google Scholar
• Stevens, DA, Horiuchi, H, Tsuizaki, M, Martinez, M, Tong, A. Not just for beta-1,3-glucan any more: caspofungin inhibition of b-1,6-glucan demonstrated at inhibitory caspofungin concentrations. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 September, 2007; Chicago, IL; 2007, M-1813.
   Google Scholar
• Pfaller M, Riley J, Koerner T. Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis 1989; 8: 1067–1070
   PubMed Web of Science ®Google Scholar
• Wiederhold, NP, Wickes, BL, Patterson, TP. Increased gene expression of mitogen-activated protein kinase A is associated with attenuated caspofungin activity in Aspergillus fumigatus. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27–30 September, 2006; San Francisco, CA; 2006: M-364.
   Google Scholar
• Kraus PR, Fox DS, Cox GM, Heitman J. The Cryptococcus, neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function. Mol Microbiol 2003; 48: 1377–1387
   PubMed Web of Science ®Google Scholar
• Fox D, Smulian AG. Mitogen-activated protein kinase Mkp1 of Pneumocystis carinii complements the slt2Delta defect in the cell integrity pathway of Saccharomyces cerevisiae. Mol Microbiol 1999; 34: 451–462
   PubMed Web of Science ®Google Scholar
• Bussink HJ, Osmani SA. A mitogen-activated protein kinase (MPKA) is involved in polarized growth in the filamentous fungus, Aspergillus nidulans. FEMS Microbiol Lett 1999; 173: 117–125
   PubMedGoogle Scholar
• Mizutani O, Nojima A, Yamamoto M, et al. Disordered cell integrity signaling caused by disruption of the kexB gene in Aspergillus oryzae. Eukaryot Cell 2004; 3: 1036–1048
   PubMedGoogle Scholar
• Reinoso-Martin C, Schuller C, Schuetzer-Muehlbauer M, Kuchler K. The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell 2003; 2: 1200–1210
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Rogers PD, Baerson SR, et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 2003; 278: 34998–35015
   PubMed Web of Science ®Google Scholar
• Munro CA, Selvaggini S, de Bruijn I, et al. The PKC, HOG and Ca2 + signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol 2007; 63: 1399–1413
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857–1869
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–4875
   PubMed Web of Science ®Google Scholar
• Lewis, RE, Albert, ND, Kontoyiannis, DP. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a persistently neutropenic murine model of invasive pulmonary aspergillosis. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17–20 September 2007; Chicago, IL; 2007: M-186.
   Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898–2905
   PubMed Web of Science ®Google Scholar
• Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381–3388
   PubMed Web of Science ®Google Scholar
• van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 732–740
   PubMed Web of Science ®Google Scholar
• Smith KR, Lank KM, Cobbs CG, Cloud GA, Dismukes WE. Comparison of cilofungin and amphotericin B for therapy of murine candidiasis. Antimicrob Agents Chemother 1990; 34: 1619–1621
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 1293–1297
   PubMed Web of Science ®Google Scholar
• Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43: e23–25
   Web of Science ®Google Scholar
• Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56: 594–597
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41: e9–14
   PubMed Web of Science ®Google Scholar
• Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53: 131–139
   PubMed Web of Science ®Google Scholar